In this video, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, describes how identifying molecular aberrations can help personalize therapy for patients with certain cancers. Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Dr Kiel stresses the need for more clinical trials to bring about further clinical advancements.
Molecular tumor boards for personalized therapy
